SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen
BIIB 167.63+1.8%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harold Engstrom who wrote (760)10/6/1998 10:01:00 AM
From: Hong-Lee Yu  Read Replies (1) of 1686
 
Harold,

I now believe that BGEN's EPS for 1999 will be close (may even above) to 3.0 as you suggested earlier. My calculation is as follows: We should see at least 120M revenue from Avonex in Q4 and 580M in 1999 (130M, 140M, 150M, 160M respectively). Royalty is 180M. Gross margin: 86.5%, R & D: 210M, tax rate: 33% and S G & A: 18% (this quarter is 18.8% and the co's goal is 17%).

Revenue
Royalty 180M
Avonex 580
Interest 30
Total: 790

Expenses:
COG: 102.6
S G & A 136.8
R & D 210
Total: 450

Pretax: 340M
After tax: 227.8
EPS: 2.92
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News